ArticleGastro hep advances2025
Bowel Urgency Severity Among Patients with Crohn's Disease or Ulcerative Colitis on Advanced Therapies: Real-World Data Using Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Vedolizumab on Bowel Urgency in Ulcerative Colitis: Post Hoc Analysis of the GEMINI 1, VISIBLE 1, and VARSITY Trials.Gastro hep advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Research on the impact of advanced therapies on bowel urgency severity in Crohn's disease (CD) and ulcerative colitis (UC) is limited. We assessed moderate-to-severe bowel urgency among patients with UC or CD at advanced therapy initiation, 6 months, and 12 months. Methods: Data from the Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease were used. Patients newly prescribed advanced therapies for CD or UC at enrollment, who completed the bowel urgency questionnaires and remained on the same advanced therapy at enrollment and at 6 months or 12 months, were included. Demographics, clinical data, and bowel urgency severity were summarized descriptively. Results: Overall, 532 patients with CD were included (332 on tumor necrosis factor inhibitors [TNFi]; 200 on non-TNFi). Moderate-to-severe bowel urgency was reported by 29.5% (enrollment) and 20.3% (12 months) in the TNFi group and 36.0% (enrollment) and 39.2% (12 months) in the non-TNFi group. Worsened urgency was noted in 21.7% (TNFi) and 19.4% (non-TNFi), while improvement was seen in 17.9% (TNFi) and 22.3% (non-TNFi). Among the 203 patients with UC (TNFi: 108; non-TNFi: 95), moderate-to-severe urgency was reported by 18.5% (enrollment) and 16.9% (12 months) in the TNFi group, and 34.7% (enrollment) and 32.1% (12 months) in the non-TNFi group. Worsened urgency was noted in 22.1% (TNFi) and 19.6% (non-TNFi), while improvement was seen in 16.9% (TNFi) and 17.9% (non-TNFi). Conclusion: Despite a year of advanced therapy, the percentage of patients with CD or UC experiencing bowel urgency remained similar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.